Bank of America’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Bank of America’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,879	Closed	-$2.65K	–	8137
2023 Q2	$2.65K	Sell	8,879 -11,398	-56%	-$3.44K	﹤0.01%	7102
2023 Q1	$8.76K	Sell	20,277 -56,450	-74%	-$43.3K	﹤0.01%	6954
2022 Q4	$90.5K	Buy	76,727 +68,169	+797%	+$111K	﹤0.01%	6265
2022 Q3	$19K	Buy	8,558 +1,889	+28%	+$4.95K	﹤0.01%	7069
2022 Q2	$14K	Sell	6,669 -30,015	-82%	-$208K	﹤0.01%	7306
2022 Q1	$353K	Buy	+36,684	New	+$329K	﹤0.01%	6066

Bank of America's GRNA Position: Q3 2023 in Review

Bank of America sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 8,879 shares — an estimated $2.65K sold.

Bank of America first reported a position in GRNA in Q1 2022 and held it in 6 quarters. The position peaked at $353K in Q1 2022. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

Bank of America reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
Bank of America sold 8,879 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $2.65K.
Bank of America first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2022 and held it in 6 quarters.
Bank of America's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $353K in Q1 2022.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on Bank of America's 13F filing for Q3 2023, filed 14 Nov 2023.